Matt Hoffman

Currently, FDA-approved fluoroquinolones include levofloxacin (Levaquin), ciprofloxacin (Cipro), ciprofloxacin extended-release tablets, moxifloxacin (Avelox), ofloxacin, gemifloxacin (Factive) and delafloxacin (Baxdela).

The issuance was in response to a request by the DoD, and after the FDA received a declaration from the Secretary of the Department of Health and Human Services.

The Center for Inquiry has filed a lawsuit against CVS for consumer fraud due to its sale and marketing of homeopathic medicines.

Peter Toth, MD, spoke about the importance of noting elevated triglycerides in patients at risk for cardiovascular conditions.

The study revealed for the first time that triglycerides can be utilized as an independent predictor of cardiovascular risk—a landmark moment.

The anti-amyloid beta protofibril antibody resulted in slowed progression in ADCOMS, as well as a reduction of amyloid-PET measured amyloid accumulation in the brain.

Recent reports have suggested a higher-than-expected rate of problematic drinking among the elderly, prompting an examination of a number of factors that could be utilized as future predictors of alcohol-related outcomes.

Despite a high level of suspicion that they triggered headache attacks from patients with migraine, a pair of studies found little to no associations between the two.

The risk of obesity was reduced by 75% for those children whose mothers partook in all 5 of the considered low-risk lifestyle factors compared to those whose mothers adhered to none.

Those with chronic migraine were much more likely to see their relationships and family lives suffer due to their condition than those with episodic migraine.

One year after the third and fourth quarterly infusions, those administered the 300-mg dose of eptinezumab reported reductions of 5.2 monthly migraine days, compared to 4.0 days for patients in the placebo group.

The poster presentations included a meta-analysis of 17 studies analyzing the cost-effectiveness and performance of the CGM system and a real-world examination of the trends its use.

Tim Dunn, PhD, discussed the benefits that the Freestyle Libre continuous glucose monitoring system provides for both the patients and providers

The LIBERATE study revealed 47.7% of those treated with the Zephyr Endobronchial Valve experienced at least a ≥15% improvement on pulmonary function scores, compared with 16.8% of the control group.

Murray Stewart, MD, spoke about his research into the hormone leptin—a major player in appetite and metabolism, with much that's still misunderstood about it.

The supplement included data from decade-long noninferiority PRECISION trial, which revealed safety data for using celecoxib in conjunction with aspirin.

In an invited commentary, a trio of authors called the concept of improving or protecting visual function as a viable intervention to prevent or control cognitive decline overall both “plausible and attractive.”

The addition of features such as Bluetooth and Wi-Fi connectivity, in addition to cloud-to-cloud integration, is essential to improving diabetes devices.

Across the 6-month duration of the trial, weight loss was maintained across all dose levels, with patients that had the lowest baseline leptin levels benefitting the most.

Patients spent 11.2% more time in their target glucose range, and hypoglycemia was reduced from 5.1% to 1.9% overall, and 5.7% to 0.7% overnight.

Grenye O'Malley, MD, spoke about study data on insulin pen priming for patients with type 1 diabetes, noting that 80% of patients reported priming frequently.

The OPTIFAST meal replacement program resulted in better outcomes than the standard of care and a higher proportion of patients no longer meeting criteria for type 2 diabetes.

Despite several of these 2 medicines have proved to reduce cardiovascular risks, that has not been the case for all options, leading to confusion.

The absolute risk reduction for patients with diabetes and recent ACS was 2.3% when on the PCSK9 inhibitor plus statin therapy.

The chief medical officer of the Joslin Diabetes Center spoke about how providers communicate with their patients can affect their adherence to medications.

As physicians treat more diverse patient populations, the importance of communicating properly with patients can have resounding effects on outcomes and adherence.

Both the intention-to-treat and on-treatment principles reported significant blood sugar reductions from the oral GLP-1 analogue.

More people achieved weight reduction of ≥5% and ≥10% with semaglutide in all BMI subgroups.

The Healthy MOMs program resulted in positive improvements in diet and depressive symptoms for expecting Latinas, a population at a high risk for gestational and type 2 diabetes.

The Janssen product was found to be linked to a reduced risk of sustained kidney function loss, attenuated eFGR decline, and a reduction in albuminuria.